博莱霉素
巨噬细胞极化
下调和上调
肺纤维化
癌症研究
特发性肺纤维化
发病机制
巨噬细胞
纤维化
化学
医学
药理学
免疫学
病理
肺
内科学
生物化学
体外
化疗
基因
作者
Yi Yang,Zhenyu Xiao,Weijie Yang,Yangyang Sun,Xin Sui,Xueyang Lin,Xinyi Yang,Zhenghao Bao,Ziqi Cui,Yingkai Ma,Weidong Li,Shengran Wang,H. J. Yang,Yongan Wang,Yuan Luo
标识
DOI:10.1007/s00018-024-05219-x
摘要
Idiopathic pulmonary fibrosis (IPF) poses significant challenges due to limited treatment options despite its complex pathogenesis involving cellular and molecular mechanisms. This study investigated the role of transient receptor potential ankyrin 1 (TRPA1) channels in regulating M2 macrophage polarization in IPF progression, potentially offering novel therapeutic targets. Using a bleomycin-induced pulmonary fibrosis model in C57BL/6J mice, we assessed the therapeutic potential of the TRPA1 inhibitor HC-030031. TRPA1 upregulation was observed in fibrotic lungs, correlating with worsened lung function and reduced survival. TRPA1 inhibition mitigated fibrosis severity, evidenced by decreased collagen deposition and restored lung tissue stiffness. Furthermore, TRPA1 blockade reversed aberrant M2 macrophage polarization induced by bleomycin, associated with reduced Smad2 phosphorylation in the TGF-β1-Smad2 pathway. In vitro studies with THP-1 cells treated with bleomycin and HC-030031 corroborated these findings, highlighting TRPA1's involvement in fibrotic modulation and macrophage polarization control. Overall, targeting TRPA1 channels presents promising therapeutic potential in managing pulmonary fibrosis by reducing pro-fibrotic marker expression, inhibiting M2 macrophage polarization, and diminishing collagen deposition. This study sheds light on a novel avenue for therapeutic intervention in IPF, addressing a critical need in the management of this challenging disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI